ALB and metabolic syndrome: Dyslipidemia is believed to decisively affect the long-term prognosis of lupus patients, not only with regard to cardiovascular events but also by influencing lupus nephritis.5 Nephrotic-range proteinuria, elevated TC level and decreased serum albumin levels not only reflect the activity but also the severity of renal damage in SLE patients.8 Studies have also shown higher degree of dyslipidemia prevalence in patients having a disease duration of 3 years, Max-SLEDAI ≥ 2 and taking Prednisone ≥ 30 mg/d.9